Why the study?
Does the use of ACE inhibitors or ARBs improve pathologic complete response and survival in primary breast cancer patients receiving neoadjuvant chemotherapy?
Population
1,449 patients with invasive primary breast cancer diagnosed at the MD Anderson Cancer Center between 1995…
Comparison
ACE inhibitors or angiotensin receptor blockers vs Non-users of ACEI/ARBs
Design
Cohort
Authors
Loading...
ACEI/ARB use shows no survival association in this cohort; hypothesis-generating and should not yet change practice.
Does the use of ACE inhibitors or ARBs improve pathologic complete response and survival in primary breast cancer patients receiving neoadjuvant chemotherapy?
ACEI/ARB use does not significantly improve survival outcomes in breast cancer patients receiving neoadjuvant chemotherapy, although ARB use alone may be associated with improved relapse-free survival.
Chae et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: